Walter Wahli

Active 1977–2025

188
Papers
49,311
Citations
110
h-index
186
i10-index

Citations

Citations per year for Walter Wahli1931: 1 citations1977: 2 citations1978: 5 citations1979: 8 citations1980: 8 citations1981: 15 citations1982: 15 citations1983: 26 citations1984: 8 citations1985: 14 citations1986: 6 citations1987: 21 citations1988: 45 citations1989: 53 citations1990: 46 citations1991: 49 citations1992: 80 citations1993: 102 citations1994: 119 citations1995: 156 citations1996: 165 citations1997: 265 citations1998: 333 citations1999: 412 citations2000: 508 citations2001: 466 citations2002: 619 citations2003: 591 citations2004: 612 citations2005: 578 citations2006: 632 citations2007: 688 citations2008: 652 citations2009: 536 citations2010: 574 citations2011: 409 citations2012: 332 citations2013: 458 citations2014: 430 citations2015: 289 citations2016: 320 citations2017: 325 citations2018: 288 citations2019: 875 citations2020: 1,156 citations2021: 1,081 citations2022: 884 citations2023: 721 citations2024: 1,001 citations2025: 464 citations2026: 7 citations1932–1976: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,520 citing papers, 28.6% of this breakdownChina: 1,837 citing papers, 11.6% of this breakdownFrance: 958 citing papers, 6% of this breakdownUnited Kingdom: 822 citing papers, 5.2% of this breakdownGermany: 713 citing papers, 4.5% of this breakdownJapan: 628 citing papers, 4% of this breakdownItaly: 579 citing papers, 3.7% of this breakdownCanada: 498 citing papers, 3.1% of this breakdownSwitzerland: 448 citing papers, 2.8% of this breakdownNetherlands: 376 citing papers, 2.4% of this breakdownSpain: 359 citing papers, 2.3% of this breakdownSouth Korea: 335 citing papers, 2.1% of this breakdown
0%28.6%Other 23.7%

Fields

  • Biochemistry, Genetics and Molecular Biology47.8%
  • Medicine35.5%
  • Neuroscience4.2%
  • Environmental Science2.6%
  • Nursing2.6%
  • Agricultural and Biological Sciences2.2%
  • Other5.1%

Topics

  • Peroxisome Proliferator-Activated Receptors9.7%
  • Adipose Tissue and Metabolism6.2%
  • Liver Disease Diagnosis and Treatment3.2%
  • Adipokines, Inflammation, and Metabolic Diseases2.6%
  • Metabolism, Diabetes, and Cancer2.5%
  • Estrogen and related hormone effects2.2%
  • Other73.6%

Coauthors

All papers

Open in search
  1. The gut microbiota influences skeletal muscle mass and function in mice

    Authors: , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2019 cited by 542

  2. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Gut 2016 cited by 731

  3. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1997 cited by 2,153

  4. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting

    Authors: , , , , , - Journal of Clinical Investigation 1999 cited by 1,642

  5. PPARs at the crossroads of lipid signaling and inflammation

    Authors: , - Trends in Endocrinology and Metabolism 2012 cited by 661

  6. Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis

    Authors: , , , , - Cells 2022 cited by 125

  7. High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine

    Authors: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 244

  8. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ

    Authors: , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2005 cited by 511

  9. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease

    Authors: , , , , - Cells 2020 cited by 138

  10. Roles of PPARs in health and disease

    Authors: , , - Nature 2000 cited by 1,967

  11. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Scientific Reports 2020 cited by 138

  12. GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK

    Authors: , , , , , , , , - Cell Reports 2021 cited by 109

  13. ATGL-dependent white adipose tissue lipolysis controls hepatocyte PPARα activity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Catherine Postic, Walter Wahli, Nicolas Loiseau, Alexandra Montagner, Dominique Langin, Achim Lass, Hervé Guillou - Cell Reports 2022 cited by 96

  14. Transcriptional Regulation of Metabolism

    Authors: , , - Physiological Reviews 2006 cited by 897

  15. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

    Authors: , , , , - Endocrinology 1996 cited by 2,149

  16. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants

    Authors: , , , , , , - Biomolecules 2020 cited by 160

  17. Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene

    Authors: , , , , , , , , - Journal of Biological Chemistry 2000 cited by 563

  18. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thierry Levade, Laurence Gamet‐Payrastre, Sandrine Lagarrigue, Nicolas Loiseau, Sophie Lotersztajn, Catherine Postic, Walter Wahli, Christophe Bureau, Maéva Guillaume, Adil Mardinoğlu, Alexandra Montagner, Pierre Gourdy, Hervé Guillou - Gut 2021 cited by 81

  19. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors

    Authors: , , , , , , , , , , , , , , , - Pharmacological Reviews 2006 cited by 988

  20. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

    Authors: , , , , , , , , , , , , , , - Liver International 2017 cited by 201

  21. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease

    Authors: , , , , , , , , , , , , , , , , , - Molecular Metabolism 2017 cited by 115

  22. PPARs and Microbiota in Skeletal Muscle Health and Wasting

    Authors: , , - International Journal of Molecular Sciences 2020 cited by 104

  23. Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*

    Authors: , - Endocrine Reviews 1999 cited by 2,889

  24. Peroxisome Proliferator-Activated Receptors and Caloric Restriction—Common Pathways Affecting Metabolism, Health, and Longevity

    Authors: , , , , - Cells 2020 cited by 77